{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:05:52Z","timestamp":1790805952053,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN 143251, PS 169193"],"award-info":[{"award-number":["FDN 143251, PS 169193"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-20-0029382"],"award-info":[{"award-number":["G-20-0029382"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jesse\u2019s Journey, Women and Children\u2019s Health Research Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59494-8","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:40:08Z","timestamp":1747212008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-1501","authenticated-orcid":false,"given":"Md Nur Ahad","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Wilton-Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhia","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooklynn","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Edellein","family":"Sutanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5730-438X","authenticated-orcid":false,"given":"Radha","family":"Maradiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0652-3235","authenticated-orcid":false,"given":"Pavel","family":"Zhabyeyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6415-6862","authenticated-orcid":false,"given":"Rohini Roy","family":"Roshmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-5923","authenticated-orcid":false,"given":"Saeed","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1759-6915","authenticated-orcid":false,"given":"Tejal","family":"Aslesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-4183","authenticated-orcid":false,"given":"Kenji Rowel Q.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0337-5425","authenticated-orcid":false,"given":"Anne","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7104-544X","authenticated-orcid":false,"given":"Melissa J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-1513","authenticated-orcid":false,"given":"Hong M.","family":"Moulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-3546","authenticated-orcid":false,"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"59494_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-00234-1","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan, D., Goemans, N., Takeda, S., Mercuri, E. & Aartsma-Rus, A. Duchenne muscular dystrophy. Nat. Rev. Dis. Prim. 7, 1\u201319 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"59494_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman, E. P., Brown, R. H. & Kunkel, L. M. Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell 51, 919\u2013928 (1987).","journal-title":"Cell"},{"key":"59494_CR3","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M. & Sweeney, H. L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA 90, 3710\u20133714 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59494_CR4","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1007\/s00246-016-1432-5","volume":"37","author":"AR Punnoose","year":"2016","unstructured":"Punnoose, A. R. et al. Cardiac disease burden and risk of mortality in hospitalized muscular dystrophy patients. Pediatr. Cardiol. 37, 1290\u20131296 (2016).","journal-title":"Pediatr. Cardiol."},{"key":"59494_CR5","doi-asserted-by":"publisher","first-page":"e030229","DOI":"10.1161\/JAHA.123.030229","volume":"12","author":"N Kashyap","year":"2023","unstructured":"Kashyap, N. et al. Prognostic utility of cardiovascular magnetic resonance\u2013based phenotyping in patients with muscular dystrophy. J. Am. Heart Assoc. 12, e030229 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"59494_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G.-J. B. & Den Dunnen, J. T. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34, 135\u2013144 (2006).","journal-title":"Muscle Nerve"},{"key":"59494_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim, K. R. Q., Maruyama, R. & Yokota, T. Eteplirsen in the treatment of Duchenne muscular dystrophy. DDDT 11, 533\u2013545 (2017).","journal-title":"DDDT"},{"key":"59494_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","volume":"56","author":"S Anwar","year":"2020","unstructured":"Anwar, S. & Yokota, T. Golodirsen for Duchenne muscular dystrophy. Drugs Today (Barc.) 56, 491\u2013504 (2020).","journal-title":"Drugs Today (Barc.)"},{"key":"59494_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","volume":"55","author":"RR Roshmi","year":"2019","unstructured":"Roshmi, R. R. & Yokota, T. Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today 55, 627\u2013639 (2019).","journal-title":"Drugs Today"},{"key":"59494_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1358\/dot.2021.57.12.3352740","volume":"57","author":"H Wilton-Clark","year":"2021","unstructured":"Wilton-Clark, H. & Yokota, T. Casimersen for Duchenne muscular dystrophy. Drugs Today 57, 707\u2013717 (2021).","journal-title":"Drugs Today"},{"key":"59494_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen, C. L. et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395\u2013402 (2015).","journal-title":"Hum. Mutat."},{"key":"59494_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2013.4908","volume":"71","author":"K Anthony","year":"2014","unstructured":"Anthony, K. et al. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. JAMA Neurol. 71, 32\u201340 (2014).","journal-title":"JAMA Neurol."},{"key":"59494_CR13","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/children10040746","volume":"10","author":"C Brogna","year":"2023","unstructured":"Brogna, C. et al. Upper limb changes in DMD patients amenable to skipping exons 44, 45, 51 and 53: a 24-month study. Children 10, 746 (2023).","journal-title":"Children"},{"key":"59494_CR14","doi-asserted-by":"publisher","first-page":"e0218683","DOI":"10.1371\/journal.pone.0218683","volume":"14","author":"C Brogna","year":"2019","unstructured":"Brogna, C. et al. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE 14, e0218683 (2019).","journal-title":"PLoS ONE"},{"key":"59494_CR15","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy, S. M. Delandistrogene moxeparvovec: first approval. Drugs 83, 1323\u20131329 (2023).","journal-title":"Drugs"},{"key":"59494_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/JND-221639","volume":"10","author":"A Lek","year":"2023","unstructured":"Lek, A., Atas, E., Hesterlee, S. E., Byrne, B. J. & B\u00f6nnemann, C. G. Meeting report: 2022 muscular dystrophy association summit on \u2018safety and challenges in gene transfer therapy\u2019. J. Neuromuscul. Dis. 10, 327\u2013336 (2023).","journal-title":"J. Neuromuscul. Dis."},{"key":"59494_CR17","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/j.nmd.2022.07.239","volume":"32","author":"H Komaki","year":"2022","unstructured":"Komaki, H. et al. P.123 a phase I\/II study of NS-089\/NCNP-02, Exon 44 skipping drug, in patients with Duchenne muscular dystrophy. Neuromuscul. Disord. 32, S99\u2013S100 (2022).","journal-title":"Neuromuscul. Disord."},{"key":"59494_CR18","unstructured":"Neurology live. Clinical Potential of AOC 1044 in Treating Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping. https:\/\/www.neurologylive.com\/view\/clinical-potential-aoc-1044-treating-duchenne-muscular-dystrophy-amenable-exon-44-skipping (2024)."},{"key":"59494_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","volume":"45","author":"MK Tsoumpra","year":"2019","unstructured":"Tsoumpra, M. K. et al. Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine 45, 630\u2013645 (2019).","journal-title":"EBioMedicine"},{"key":"59494_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm1345","volume":"12","author":"J Alter","year":"2006","unstructured":"Alter, J. et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175\u2013177 (2006).","journal-title":"Nat. Med."},{"key":"59494_CR21","doi-asserted-by":"publisher","first-page":"175628642311829","DOI":"10.1177\/17562864231182934","volume":"16","author":"MNA Shah","year":"2023","unstructured":"Shah, M. N. A. & Yokota, T. Cardiac therapies for Duchenne muscular dystrophy. Ther. Adv. Neurol. Disord. 16, 17562864231182934 (2023).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"59494_CR22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112546119","volume":"119","author":"KRQ Lim","year":"2022","unstructured":"Lim, K. R. Q. et al. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 119, e2112546119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59494_CR23","doi-asserted-by":"crossref","unstructured":"Aslesh, T. et al. DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration. JCI Insight 8, e160516 (2023).","DOI":"10.1172\/jci.insight.160516"},{"key":"59494_CR24","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.3390\/cells12192395","volume":"12","author":"US Haque","year":"2023","unstructured":"Haque, U. S. & Yokota, T. Enhancing antisense oligonucleotide-based therapeutic delivery with dg9, a versatile cell-penetrating peptide. Cells 12, 2395 (2023).","journal-title":"Cells"},{"key":"59494_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/JND-170218","volume":"4","author":"CS Young","year":"2017","unstructured":"Young, C. S., Mokhonova, E., Quinonez, M., Pyle, A. D. & Spencer, M. J. Creation of a novel humanized dystrophic mouse model of duchenne muscular dystrophy and application of CRISPR\/Cas9 gene editing therapy. J. Neuromuscul. Dis. 4, 139\u2013145 (2017).","journal-title":"J. Neuromuscul. Dis."},{"key":"59494_CR26","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1126\/science.2662404","volume":"244","author":"P Sicinski","year":"1989","unstructured":"Sicinski, P. et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578\u20131580 (1989).","journal-title":"Science"},{"key":"59494_CR27","doi-asserted-by":"publisher","first-page":"e0120058","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya, Y., Mouly, V., Garcia, L., Yokota, T. & Duddy, W. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in duchenne muscular dystrophy. PLoS ONE 10, e0120058 (2015).","journal-title":"PLoS ONE"},{"key":"59494_CR28","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1093\/nar\/gkt1220","volume":"42","author":"T Lehto","year":"2014","unstructured":"Lehto, T. et al. Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res. 42, 3207\u20133217 (2014).","journal-title":"Nucleic Acids Res."},{"key":"59494_CR29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/mus.21211","volume":"39","author":"CF Spurney","year":"2009","unstructured":"Spurney, C. F. et al. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 39, 591\u2013602 (2009).","journal-title":"Muscle Nerve"},{"key":"59494_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.nmd.2004.04.007","volume":"14","author":"JG Quinlan","year":"2004","unstructured":"Quinlan, J. G. et al. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul. Disord. 14, 491\u2013496 (2004).","journal-title":"Neuromuscul. Disord."},{"key":"59494_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.yjmcc.2019.01.013","volume":"128","author":"TA Meyers","year":"2019","unstructured":"Meyers, T. A. et al. Acute AT1R blockade prevents isoproterenol-induced injury in mdx hearts. J. Mol. Cell. Cardiol. 128, 51\u201361 (2019).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"59494_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz2736","volume":"6","author":"L Yu","year":"2020","unstructured":"Yu, L. et al. Small-molecule activation of lysosomal TRP channels ameliorates Duchenne muscular dystrophy in mouse models. Sci. Adv. 6, eaaz2736 (2020).","journal-title":"Sci. Adv."},{"key":"59494_CR33","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1093\/hmg\/ddh174","volume":"13","author":"Y Yue","year":"2004","unstructured":"Yue, Y., Skimming, J. W., Liu, M., Strawn, T. & Duan, D. Full-length dystrophin expression in half of the heart cells ameliorates \u03b2-isoproterenol-induced cardiomyopathy in mdx mice. Hum. Mol. Genet. 13, 1669\u20131675 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"59494_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.yjmcc.2014.08.013","volume":"76","author":"J Strakova","year":"2014","unstructured":"Strakova, J. et al. Dystrobrevin increases dystrophin\u2019s binding to the dystrophin\u2013glycoprotein complex and provides protection during cardiac stress. J. Mol. Cell. Cardiol. 76, 106\u2013115 (2014).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"59494_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","volume":"62","author":"WK Han","year":"2002","unstructured":"Han, W. K., Bailly, V., Abichandani, R., Thadhani, R. & Bonventre, J. V. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62, 237\u2013244 (2002).","journal-title":"Kidney Int."},{"key":"59494_CR36","doi-asserted-by":"crossref","unstructured":"Nieves-Rodriguez, S. et al. Transcriptomic analysis of paired healthy human skeletal muscles to identify modulators of disease severity in DMD. Front. Genet. 14, 1216066 (2023).","DOI":"10.3389\/fgene.2023.1216066"},{"key":"59494_CR37","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jacc.2019.12.066","volume":"75","author":"F Kamdar","year":"2020","unstructured":"Kamdar, F. et al. Stem cell\u2013derived cardiomyocytes and beta-adrenergic receptor blockade in duchenne muscular dystrophy cardiomyopathy. J. Am. Coll. Cardiol. 75, 1159\u20131174 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"59494_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"59494_CR39","unstructured":"Sarepta Therapeutics. Community Letter: Update SRP-5051 Program. https:\/\/www.sarepta.com\/community-letter-update-srp-5051-program (2024)."},{"key":"59494_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.30","volume":"1","author":"C Betts","year":"2012","unstructured":"Betts, C. et al. Pip6-PMO, A new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nucleic Acids 1, e38 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"59494_CR41","doi-asserted-by":"publisher","first-page":"102623","DOI":"10.1016\/j.nano.2022.102623","volume":"47","author":"M Repellin","year":"2023","unstructured":"Repellin, M. et al. Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy. Nanomed.: Nanotechnol. Biol. Med. 47, 102623 (2023).","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"key":"59494_CR42","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.4081\/ejh.2009.e31","volume":"53","author":"L Casadei","year":"2009","unstructured":"Casadei, L. et al. Proteomics-based investigation in C2C12 myoblast differentiation. Eur. J. Histochem. 53, e31 (2009).","journal-title":"Eur. J. Histochem."},{"key":"59494_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajpath.2011.03.050","volume":"179","author":"EP Hoffman","year":"2011","unstructured":"Hoffman, E. P. et al. Restoring dystrophin expression in Duchenne muscular dystrophy muscle. Am. J. Pathol. 179, 12\u201322 (2011).","journal-title":"Am. J. Pathol."},{"key":"59494_CR44","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","volume":"22","author":"Y Aoki","year":"2013","unstructured":"Aoki, Y. et al. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-\u03b12 chain-null congenital muscular dystrophy mice. Hum. Mol. Genet. 22, 4914\u20134928 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"59494_CR45","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.omtn.2019.01.008","volume":"14","author":"S Miyatake","year":"2019","unstructured":"Miyatake, S. et al. Scavenger receptor class A1 mediates uptake of morpholino antisense oligonucleotide into dystrophic skeletal muscle. Mol. Ther. Nucleic Acids 14, 520\u2013535 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"59494_CR46","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki, Y. et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52\u2013deficient mdx mouse. Mol. Ther. 18, 1995\u20132005 (2010).","journal-title":"Mol. Ther."},{"key":"59494_CR47","doi-asserted-by":"crossref","unstructured":"Watanabe, N. et al. Exon 44 skipping in Duchenne muscular dystrophy: NS-089\/NCNP-02, a dual-targeting antisense oligonucleotide. Mol. Ther. Nucleic Acids 34, 102034 (2023).","DOI":"10.1016\/j.omtn.2023.102034"},{"key":"59494_CR48","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/cvr\/cvab232","volume":"118","author":"F Canonico","year":"2022","unstructured":"Canonico, F. et al. Focus on the road to modelling cardiomyopathy in muscular dystrophy. Cardiovasc. Res. 118, 1872\u20131884 (2022).","journal-title":"Cardiovasc. Res."},{"key":"59494_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.braindev.2007.01.009","volume":"29","author":"T Matsumura","year":"2007","unstructured":"Matsumura, T., Saito, T., Fujimura, H. & Shinno, S. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. Brain Dev. 29, 496\u2013501 (2007).","journal-title":"Brain Dev."},{"key":"59494_CR50","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1093\/nar\/gkm478","volume":"35","author":"RP Wu","year":"2007","unstructured":"Wu, R. P. et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res. 35, 5182\u20135191 (2007).","journal-title":"Nucleic Acids Res."},{"key":"59494_CR51","doi-asserted-by":"crossref","unstructured":"Shah, M. N. A. & Yokota, T. Restoring dystrophin expression by skipping exons 6 and 8 in neonatal dystrophic dogs. In Muscular Dystrophy Therapeutics: Methods and Protocols (eds. Maruyama, R. & Yokota, T.) 107\u2013124 (Springer US, New York, NY, 2023).","DOI":"10.1007\/978-1-0716-2772-3_6"},{"key":"59494_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13395-018-0186-6","volume":"9","author":"T Desgeorges","year":"2019","unstructured":"Desgeorges, T. et al. Open-CSAM, a new tool for semi-automated analysis of myofiber cross-sectional area in regenerating adult skeletal muscle. Skelet. Muscle 9, 1\u201312 (2019).","journal-title":"Skelet. Muscle"},{"key":"59494_CR53","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/bioinformatics\/btaa847","volume":"37","author":"G Landini","year":"2021","unstructured":"Landini, G., Martinelli, G. & Piccinini, F. Colour deconvolution: stain unmixing in histological imaging. Bioinformatics 37, 1485\u20131487 (2021).","journal-title":"Bioinformatics"},{"key":"59494_CR54","first-page":"291","volume":"23","author":"AC Ruifrok","year":"2001","unstructured":"Ruifrok, A. C. & Johnston, D. A. Quantification of histochemical staining by color deconvolution. Anal. Quant. Cytol. Histol. 23, 291\u2013299 (2001).","journal-title":"Anal. Quant. Cytol. Histol."},{"key":"59494_CR55","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"59494_CR56","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nmeth.4324","volume":"14","author":"H Pimentel","year":"2017","unstructured":"Pimentel, H., Bray, N. L., Puente, S., Melsted, P. & Pachter, L. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat. Methods 14, 687\u2013690 (2017).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59494-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59494-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59494-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T10:03:40Z","timestamp":1747217020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59494-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59494"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59494-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.Y. and Rika M. are cofounders of OligomicsTx Inc., which aims to commercialize antisense technology. The rest of the authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4477"}}